Trending

liver disease

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

An FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type

X

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

https://pharmaphorum.com/news/mallinckrodts-liver-disease-drug-terlipressin-edges-fda-advisory-panel/

COVID-19 and vulnerable children: Urging caution while enjoying childhood

COVID-19 and vulnerable children: Urging caution while enjoying childhood

How do you keep a child with a suppressed immune system safe during COVID-19 lockdown? And how do

X

COVID-19 and vulnerable children: Urging caution while enjoying childhood

https://pharmaphorum.com/views-analysis-patients/covid-19-vulnerable-children/

Q&A: Novartis’ Eric Hughes on transplantation

Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems

X

Q&A: Novartis’ Eric Hughes on transplantation

https://pharmaphorum.com/r-d/views-analysis-r-d/novartis-eric-hughes-transplantation/

Conatus axes staff after latest failure of Novartis-partnered NASH drug

Conatus axes staff after latest failure of Novartis-partnered NASH drug

Conatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects

X

Conatus axes staff after latest failure of Novartis-partnered NASH drug

https://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/

Gilead NASH drug fails late stage trial

Gilead NASH drug fails late stage trial

Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a

X

Gilead NASH drug fails late stage trial

https://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/

Promethera looks to Asia with €10m investment

Promethera looks to Asia with €10m investment

Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of

X

Promethera looks to Asia with €10m investment

https://pharmaphorum.com/news/promethera-looks-to-asia-with-e10m-investment/

Novartis muscles into NASH fatty liver disease

Novartis muscles into NASH fatty liver disease

Company’s Eric Hughes on what it takes to be leader in NASH – and what can be learnt from hepatitis C.

X

Novartis muscles into NASH fatty liver disease

https://pharmaphorum.com/views-and-analysis/novartis-muscles-nash-fatty-liver-disease/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com